National shareholders rights firm Hagens Berman continues to investigate the legal claims and urges Hims & Hers investors who suffered substantial losses to submit your losses now . The firm also ...

Three studies presented today at the Society of NeuroInterventional Surgery's (SNIS) 22nd Annual Meeting discussed whether ...

New and disturbing concerns about fake GLP-1 drugs are cited in a letter sent to the FDA by Tennessee officials, including Sen. Marsha Blackburn.

Older age and female sex may be associated with greater muscle loss in adults with obesity prescribed semaglutide, and ...

Hims & Hers Health, Inc.’s HIMS investors have been experiencing some short-term gains from the stock lately despite its ...

Pointing to Ozempic as a paradigm shift, an elite rehab center is experimenting with GLP-1s to tame many forms of addiction.

Executives and directors of Hims & Hers Health Inc., a leading telehealth company, are facing a shareholder derivative ...

Improving Global Outcomes (KDIGO) group has updated chronic kidney disease treatment guidelines to help slow disease progression in adults. A JAMA article published Wednesday summarized the revised ...

Presented by AstraZeneca{beacon} Health Care Health Care   The Big Story CMS targets hospitals with site-neutral drug ruleThe ...

Newly published research claims those taking GLP-1 jabs are at a 37 percent lower risk of dementia than those on the anti-diabetic medication.

Benefits were most prominent among women, patients older than 60 and those with a body mass index of 30 to 40.